Safety, Pharmacokinetic, and Efficacy Studies of Oral DB868 in a First Stage Vervet Monkey Model of Human African Trypanosomiasis
Figure 5
Changes in plasma biomarkers of kidney injury in uninfected vervet monkeys administered DB868.
DB868 was administered orally at 10 mg/kg/day (n = 4) or 30 mg/kg/day (n = 4) for 10 days, day −9 to day 0 post-last drug dose. Symbols and error bars represent means and SEs, respectively, of (A) creatinine and (B) urea.